Natera Inc. said it has changed its executive and director pay packages so that with salaries and retainers will be taken in common stock for the rest of 2022. The change by the cell-free DNA testing company comes after the stock, which dropped 6.7% in premarket trading toward a 22-month low, has plunged 62.5% over the past 12 months through Friday, while the iShares Biotechnology ETF has lost 22.0% and the S&P 500 has gained 6.6%. “We are taking this step to express our confidence in Natera’s strong fundamentals and future business outlook,” said Natera Chief Executive Steve Chapman. In 2020, Chapman’s salary of $486,732 represented 6.0% of his total compensation of $8.08 million, which included stock awards valued at $5.5 million. The company has not yet released its proxy statement for 2021.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
